Bexson Biomedical is developing a version of ketamine that would offer an alternative to opiates for postoperative pain management.  In September, the company won patent protection for its SeValent novel formulation technology that would enable at-home therapy with a wearable device instead of in-hospital IV delivery.  The on-body delivery system, developed jointly with Stevanato Group, includes…